Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole
Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole
复制标题
比卡鲁胺引起的男性乳房发育症和乳房疼痛的预防和治疗：他莫昔芬和阿那曲唑的随机内分泌学和临床研究
DOI：
--
复制
发表时间：
2005
影响因子：
4.8
通讯作者：
J. Gallo
中科院分区：
文献类型：
--
作者：
D. Saltzstein;Paul Sieber;Thomas Morris;J. Gallo
一项随机、双盲、安慰剂对照的多中心试验，涉及107名接受前列腺癌根治性治疗后接受比卡鲁胺（“Casodex”）150 mg/天治疗的男性，评估了他莫昔芬（“Nolvadex”）20 mg/天和阿那曲唑（“Arimidex”）1 mg/天预防和治疗男性乳房发育/乳房疼痛。他莫昔芬，而不是阿那曲唑，显着降低男性乳房发育/乳房疼痛的发生率时，使用的药物和治疗。与安慰剂组相比，他莫昔芬组血清睾酮水平升高，但所有治疗组的前列腺特异性抗原水平下降。需要进一步的研究来确定最佳的他莫昔芬剂量，并评估对癌症控制的任何影响。在这种情况下使用他莫昔芬仍有待研究。
A randomized, double-blind, placebo-controlled multicenter trial involving 107 men receiving bicalutamide (‘Casodex’) 150 mg/day therapy following radical therapy for prostate cancer assessed tamoxifen (‘Nolvadex’) 20 mg/day and anastrozole (‘Arimidex’) 1 mg/day for the prophylaxis and treatment of gynecomastia/breast pain. Tamoxifen, but not anastrozole, significantly reduced the incidence of gynecomastia/breast pain when used prophylactically and therapeutically. Serum testosterone levels increased with tamoxifen relative to placebo but prostate-specific antigen levels declined in all treatment groups. Further studies are needed to define the optimum tamoxifen dose and to assess any impact on cancer control. The use of tamoxifen in this setting remains to be investigated.